Modeling, Synthesis and Biological Evaluation of Potential RetinoidX Receptor-Selective Agonists

Novel Halogenated Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene)

Julie K. Furmick, Ichiro Kaneko, Angela N. Walsh, Joanna Yang, Jaskaran S. Bhogal, Geoffrey M. Gray, Juan C. Baso, Drew O. Browder, Jessica L S Prentice, Luis A. Montano, Chanh C. Huynh, Lisa M. Marcus, Dorian G. Tsosie, Jungeun S. Kwon, Alexis Quezada, Nicole M. Reyes, Brittney Lemming, Puneet Saini, Arjan vanderVaart, Thomas L. Groy & 3 others Pamela Marshall, Peter Jurutka, Carl Wagner

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The synthesis of halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (1), known commonly as bexarotene, and their evaluation for retinoidX receptor (RXR)-specific agonist performance is described. Compound 1 is FDA approved to treat cutaneous T-cell lymphoma (CTCL); however, bexarotene treatment can induce hypothyroidism and elevated triglyceride levels, presumably by disrupting RXR heterodimer pathways for other nuclear receptors. The novel halogenated analogues in this study were modeled and assessed for their ability to bind to RXR and stimulate RXR homodimerization in an RXRE-mediated transcriptional assay as well as an RXR mammalian-2-hybrid assay. In an array of eight novel compounds, four analogues were discovered to promote RXR-mediated transcription with EC50 values similar to that of 1 and are selective RXR agonists. Our approach also uncovered a periodic trend of increased binding and homodimerization of RXR when substituting a halogen atom for a proton ortho to the carboxylic acid on 1.

Original languageEnglish (US)
Pages (from-to)1551-1566
Number of pages16
JournalChemMedChem
Volume7
Issue number9
DOIs
StatePublished - Sep 2012

Fingerprint

Benzoic Acid
Assays
Cutaneous T-Cell Lymphoma
Halogens
T-cells
Transcription
Cytoplasmic and Nuclear Receptors
Carboxylic Acids
Hypothyroidism
Protons
Triglycerides
Atoms
bexarotene

Keywords

  • Bexarotene
  • Cutaneous T-cell lymphomas
  • Retinoic acid receptors
  • RetinoidX receptors
  • Rexinoids

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry
  • Molecular Medicine

Cite this

Modeling, Synthesis and Biological Evaluation of Potential RetinoidX Receptor-Selective Agonists : Novel Halogenated Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene). / Furmick, Julie K.; Kaneko, Ichiro; Walsh, Angela N.; Yang, Joanna; Bhogal, Jaskaran S.; Gray, Geoffrey M.; Baso, Juan C.; Browder, Drew O.; Prentice, Jessica L S; Montano, Luis A.; Huynh, Chanh C.; Marcus, Lisa M.; Tsosie, Dorian G.; Kwon, Jungeun S.; Quezada, Alexis; Reyes, Nicole M.; Lemming, Brittney; Saini, Puneet; vanderVaart, Arjan; Groy, Thomas L.; Marshall, Pamela; Jurutka, Peter; Wagner, Carl.

In: ChemMedChem, Vol. 7, No. 9, 09.2012, p. 1551-1566.

Research output: Contribution to journalArticle

Furmick, JK, Kaneko, I, Walsh, AN, Yang, J, Bhogal, JS, Gray, GM, Baso, JC, Browder, DO, Prentice, JLS, Montano, LA, Huynh, CC, Marcus, LM, Tsosie, DG, Kwon, JS, Quezada, A, Reyes, NM, Lemming, B, Saini, P, vanderVaart, A, Groy, TL, Marshall, P, Jurutka, P & Wagner, C 2012, 'Modeling, Synthesis and Biological Evaluation of Potential RetinoidX Receptor-Selective Agonists: Novel Halogenated Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene)', ChemMedChem, vol. 7, no. 9, pp. 1551-1566. https://doi.org/10.1002/cmdc.201200319
Furmick, Julie K. ; Kaneko, Ichiro ; Walsh, Angela N. ; Yang, Joanna ; Bhogal, Jaskaran S. ; Gray, Geoffrey M. ; Baso, Juan C. ; Browder, Drew O. ; Prentice, Jessica L S ; Montano, Luis A. ; Huynh, Chanh C. ; Marcus, Lisa M. ; Tsosie, Dorian G. ; Kwon, Jungeun S. ; Quezada, Alexis ; Reyes, Nicole M. ; Lemming, Brittney ; Saini, Puneet ; vanderVaart, Arjan ; Groy, Thomas L. ; Marshall, Pamela ; Jurutka, Peter ; Wagner, Carl. / Modeling, Synthesis and Biological Evaluation of Potential RetinoidX Receptor-Selective Agonists : Novel Halogenated Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene). In: ChemMedChem. 2012 ; Vol. 7, No. 9. pp. 1551-1566.
@article{11b1e46034a54cb2bb13a06b125cfafb,
title = "Modeling, Synthesis and Biological Evaluation of Potential RetinoidX Receptor-Selective Agonists: Novel Halogenated Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene)",
abstract = "The synthesis of halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (1), known commonly as bexarotene, and their evaluation for retinoidX receptor (RXR)-specific agonist performance is described. Compound 1 is FDA approved to treat cutaneous T-cell lymphoma (CTCL); however, bexarotene treatment can induce hypothyroidism and elevated triglyceride levels, presumably by disrupting RXR heterodimer pathways for other nuclear receptors. The novel halogenated analogues in this study were modeled and assessed for their ability to bind to RXR and stimulate RXR homodimerization in an RXRE-mediated transcriptional assay as well as an RXR mammalian-2-hybrid assay. In an array of eight novel compounds, four analogues were discovered to promote RXR-mediated transcription with EC50 values similar to that of 1 and are selective RXR agonists. Our approach also uncovered a periodic trend of increased binding and homodimerization of RXR when substituting a halogen atom for a proton ortho to the carboxylic acid on 1.",
keywords = "Bexarotene, Cutaneous T-cell lymphomas, Retinoic acid receptors, RetinoidX receptors, Rexinoids",
author = "Furmick, {Julie K.} and Ichiro Kaneko and Walsh, {Angela N.} and Joanna Yang and Bhogal, {Jaskaran S.} and Gray, {Geoffrey M.} and Baso, {Juan C.} and Browder, {Drew O.} and Prentice, {Jessica L S} and Montano, {Luis A.} and Huynh, {Chanh C.} and Marcus, {Lisa M.} and Tsosie, {Dorian G.} and Kwon, {Jungeun S.} and Alexis Quezada and Reyes, {Nicole M.} and Brittney Lemming and Puneet Saini and Arjan vanderVaart and Groy, {Thomas L.} and Pamela Marshall and Peter Jurutka and Carl Wagner",
year = "2012",
month = "9",
doi = "10.1002/cmdc.201200319",
language = "English (US)",
volume = "7",
pages = "1551--1566",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Modeling, Synthesis and Biological Evaluation of Potential RetinoidX Receptor-Selective Agonists

T2 - Novel Halogenated Analogues of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene)

AU - Furmick, Julie K.

AU - Kaneko, Ichiro

AU - Walsh, Angela N.

AU - Yang, Joanna

AU - Bhogal, Jaskaran S.

AU - Gray, Geoffrey M.

AU - Baso, Juan C.

AU - Browder, Drew O.

AU - Prentice, Jessica L S

AU - Montano, Luis A.

AU - Huynh, Chanh C.

AU - Marcus, Lisa M.

AU - Tsosie, Dorian G.

AU - Kwon, Jungeun S.

AU - Quezada, Alexis

AU - Reyes, Nicole M.

AU - Lemming, Brittney

AU - Saini, Puneet

AU - vanderVaart, Arjan

AU - Groy, Thomas L.

AU - Marshall, Pamela

AU - Jurutka, Peter

AU - Wagner, Carl

PY - 2012/9

Y1 - 2012/9

N2 - The synthesis of halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (1), known commonly as bexarotene, and their evaluation for retinoidX receptor (RXR)-specific agonist performance is described. Compound 1 is FDA approved to treat cutaneous T-cell lymphoma (CTCL); however, bexarotene treatment can induce hypothyroidism and elevated triglyceride levels, presumably by disrupting RXR heterodimer pathways for other nuclear receptors. The novel halogenated analogues in this study were modeled and assessed for their ability to bind to RXR and stimulate RXR homodimerization in an RXRE-mediated transcriptional assay as well as an RXR mammalian-2-hybrid assay. In an array of eight novel compounds, four analogues were discovered to promote RXR-mediated transcription with EC50 values similar to that of 1 and are selective RXR agonists. Our approach also uncovered a periodic trend of increased binding and homodimerization of RXR when substituting a halogen atom for a proton ortho to the carboxylic acid on 1.

AB - The synthesis of halogenated analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (1), known commonly as bexarotene, and their evaluation for retinoidX receptor (RXR)-specific agonist performance is described. Compound 1 is FDA approved to treat cutaneous T-cell lymphoma (CTCL); however, bexarotene treatment can induce hypothyroidism and elevated triglyceride levels, presumably by disrupting RXR heterodimer pathways for other nuclear receptors. The novel halogenated analogues in this study were modeled and assessed for their ability to bind to RXR and stimulate RXR homodimerization in an RXRE-mediated transcriptional assay as well as an RXR mammalian-2-hybrid assay. In an array of eight novel compounds, four analogues were discovered to promote RXR-mediated transcription with EC50 values similar to that of 1 and are selective RXR agonists. Our approach also uncovered a periodic trend of increased binding and homodimerization of RXR when substituting a halogen atom for a proton ortho to the carboxylic acid on 1.

KW - Bexarotene

KW - Cutaneous T-cell lymphomas

KW - Retinoic acid receptors

KW - RetinoidX receptors

KW - Rexinoids

UR - http://www.scopus.com/inward/record.url?scp=84865588763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865588763&partnerID=8YFLogxK

U2 - 10.1002/cmdc.201200319

DO - 10.1002/cmdc.201200319

M3 - Article

VL - 7

SP - 1551

EP - 1566

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 9

ER -